<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102458">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01835860</url>
  </required_header>
  <id_info>
    <org_study_id>REB-12-81</org_study_id>
    <nct_id>NCT01835860</nct_id>
  </id_info>
  <brief_title>Prostatic Artery Embolization for Benign Prostatic Hyperplasia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regina Qu'Appelle Health Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regina Qu'Appelle Health Region</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether Prostatic Artery Embolization (PAE) might be an effective alternative
      treatment option for benign prostatic hyperplasia (BPH), in comparison to current gold
      standard surgical treatment- Transurethral Resection of Prostate (TURP).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in symptom severity at 1, 3, 6 and 12 months follow-up, as measured by International prostate symptoms score (IPSS).</measure>
    <time_frame>1, 3, 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Benign Prostate Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Embolization</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Prostate artery embolization</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prostate artery embolization</intervention_name>
    <arm_group_label>Embolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Moderate to severe lower urinary tract symptoms (i.e. International prostate symptom
             score IPSS&gt;8) who are bothered by their symptoms (i.e., interfere with the daily
             activities of living)

          2. Urinary retention (related to BPH) leading to catheterization.

          3. Refractory to medical treatment or patient is not willing to consider medical
             treatment

          4. Pre trans-urethral resection of prostate (TURP) to reduce the size of prostate gland
             if prostate is too big for TURP surgery.

        Exclusion Criteria:

          1. Mild symptoms (IPSS &lt;8)

          2. Moderate to severe lower urinary tract symptoms (i.e. IPSS&gt;8) who are not bothered by
             their symptoms (i.e., symptoms do not interfere with the daily activities of living).

          3. Suspected malignancy.

          4. Any of the following clearly related to BPH- bladder stones, recurrent UTIs, and
             renal insufficiency.

          5. Advanced atherosclerosis and unsuitable vascular access.

          6. Allergy to intravenous contra
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patanjali Chaturvedi, FRCPC</last_name>
    <phone>1(306)-7663715</phone>
    <email>patanjali_c@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regina General Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4P 0W5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patanjali Chaturvedi, FRCPC</last_name>
      <phone>1(306)-7663715</phone>
      <email>patanjali_c@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Patanjali Chaturvedi, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed Farooq, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abdussalam Abujhar, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erwin Karreman, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>June Zimmer, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorna Montanini</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 16, 2013</lastchanged_date>
  <firstreceived_date>March 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BPH</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
